Table 1 Baseline characteristics of the study population
From: Prophylactic para-aortic lymph node dissection in Colo-rectal cancer; pilot study
Characteristic | Number (%) |
|---|---|
Sex | |
 • Male | 35 (58.3%) |
 • Female | 25 (41.7%) |
BMI | |
 • Obese | 43 (71.7%) |
 • Normal range | 17 (28.3%) |
Medical comorbidity | |
 • Yes | 14 (23.3%) |
 - DM | 3 (21.4%) |
 - DM & HTN | 5 (35.7%) |
 - HTN | 6 (42.9%) |
 • No | 46 (46.7%) |
Family history of malignancy (colorectal cancer) | |
 • Yes | 11 (18.3%) |
 • No | 49 (81.7%) |
Complaint | |
 • Constipation & rectal bleeding | 39 (65%) |
 • Constipation only | 21 (35%) |
Location of the tumor | |
 • Descending colon | 21 (35%) |
 • Sigmoid | 22 (36.7%) |
 • Recto-sigmoid | 11 (18.3%) |
 • Upper rectum | 6 (10%) |
Laboratory investigations | |
 • HB level (gm/dl) | |
  - More than 10 | 46 (76.7%) |
  - Less than 10 | 14 (23.3%) |
 • CA19.9 level (ng/dl) | |
  - More than 35 | 5 (8.3%) |
  - Less than 35 | 55 (91.7%) |
 • CEA level (ng/dl) | |
  - More than 20 | 8 (13.3%) |
  - Less than 20 | 52 (86.7%) |
Radiological investigations | |
 • MRI pelvis & triphasic CT | 40 (66.7%) |
 • Triphasic CT only | 20 (33.3%) |
Pathological data (pre-operative) | |
 • Pathological variant of tumor | |
  - Adenocarcinoma | 60 (100%) |
 • Pathological grade | |
  - Grade 2 | 55 (91.7%) |
  - Grade 3 | 5 (8.3%) |
Neo-adjuvant therapy | |
 • Neoadjuvant chemotherapy | |
  - Yes | 3 (5%) |
  - No | 57 (95%) |
 • Neoadjuvant radiotherapy |  |
  - Yes | 6 (10%) |
  - No | 54 (90%) |
Operative details | |
 • Operative procedure | |
  - Left hemicolectomy | 21 (35%) |
  - Sigmoid colectomy | 20 (33.3%) |
  - Sigmoid colectomy & hepatic metastasectomy | 2 (3.3%) |
  - LAR | 16 (26.7%) |
  - LAR & hepatic metastasectomy | 1 (1.7%) |
 • Operative time (in minutes) | |
  - Less than 120 min | 42 (70%) |
  - More than 120 min | 18 (30%) |
Hospital stay (in days) | |
 • Less than 7 days | 43 (71.7%) |
 • More than 7 days | 17 (28.3%) |
Post-Operative Complications | |
 • Wound infection | |
  - Yes | 6 (10%) |
  - No | 54 (90%) |
 • Lymphorrhea | |
  - Yes | 2 (3.3%) |
  - No | 58 (96.7%) |
Pathological data (post-Operative) | |
 • Pathological variant | |
  - Adenocarcinoma | 60 (100%) |
 • Grade | |
  - Grade 2 | 55 (91.7%) |
  - Grade 3 | 5 (8.3%) |
 • Depth of invasion | |
  - Infiltrating non-periodized fat | 60 (100%) |
 • Margins of resection | |
  - Negative margins (R0 resection) | 60 (100%) |
  - Positive margins (R1 or R2 resection) | Zero |
 • Lymphovascular invasion | |
  - Positive | 36 (60%) |
  - Negative | 24 (40%) |
 • Perineural invasion | |
  - Positive | 10 (16.7%) |
  - Negative | 50 (83.3%) |
• Resected Mesenteric LNs | |
 - Number harvested | |
  # More than 25 LNs | 23 (38.3%) |
  # Less than 25 LNs | 37 (61.7%) |
  - Positive LNs | 36 (60%) |
  - Negative LNs | 24 (40%) |
• Resected Para-aortic LNs | |
 - Number harvested | |
  # More than 8 LNs | 23 (38.3%) |
  # Less than 8 LNs | 37 (61.7%) |
  - Positive LNs | 10 (16.6%) |
  - Negative LNs | 50 (83.4%) |
• Resected HFLs among hepatic metastasectomy cases | 3 (100% among those cases) |
Recurrence | |
 • Site of recurrence | |
  - Nodal recurrence | 4 (6.7%) |
  - Multiple recurrence sites (nodal, peritoneal & liver) | 4 (6.7%) |
 • Interval time | |
  - Less than one year | 4 (6.7%) |
  - More than one year | 4 (6.7%) |
 • Treatment | |
  - CTH then surgery | 4 (6.7%) |
  - CTH and palliative therapy | 4 (6.7%) |
 • Fate & prognosis | |
  - Good prognosis | 4 (6.7%) |
  - Poor prognosis | 4 (6.7%) |